The Weill Cornell Medical College - New Jersey Medical School Clinical Trials Unit (WCMC-NJMS CTU) will conduct National Institute of Allergy and Infectious Diseases (NIAID)-sponsored network studies of HIV treatment and HIV prevention and enroll participants from communities of the New York City (NYC)-Newark metropolitan area, the epicenter of HIV in the U.S. The unit consists of a central core and three clinical research sites (CRS). The WCMC-NJMS CTU provides central research support to the three CRS, including investigative oversight;financial administration;coordination of laboratories, pharmacy, regulatory assurance, data management, quality assurance, training;and community engagement. The three CRS, WCMC-Uptown, WCMC-Chelsea, and NJMS-Newark are located in different parts of the NYC-Newark metropolitan area and serve distinct, racially and ethnically diverse patient populations of HIV-infected and at-risk individuals. WCMC-Uptown CRS is located close to Harlem, a neighborhood with an HIV seroprevalence rate of nearly 3%. The WCMC-Chelsea CRS is located in Chelsea, the neighborhood with the highest HIV seroprevalence rate in NYC of over 4%. The NJMS-Newark CRS is located in the center of Newark, and serves a predominately African American population with a seroprevalence of 3%. WCMCNJMS CTU investigators are leaders in the field who are shaping the HIV treatment and HIV prevention research agendas. They are highly experienced with expertise in non-infectious complications of HIV;HCV studies of both mono- and co-infected individuals;tuberculosis, including cutting-edge diagnostics;HIV related malignancies;novel antiretrovirals;and HIV prevention, including studies of pre-exposure prophylaxis (PrEP) to prevent HIV acquisition. Community engagement is a key strength of the WCMC-NJMS CTU with both site-specific and joint Community Advisory Boards (CAB), and a strong record of effectively communicating study results back to the community. In summary, the WCMC-NJMS CTU brings together a diverse group of recognized investigator leaders who will work with an experienced clinical research staff to conduct cutting-edge HIV treatment and HIV prevention studies in the NYC-Newark metropolitan area.
Over 1 million Americans currently are living with HIV infection and 50,000 Americans are newly infected with HIV each year. The New York City - Newark metropolitan area is the most affected area of the U.S. with over 100,000 people living with HIV infection and over 3500 newly infected with HIV each year. The WCMC-NJMS CTU will conduct studies of HIV treatment and HIV prevention to advance the field.
|Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
|Taiwo, Babafemi O; Zheng, Lu; Stefanescu, Andrei et al. (2018) ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 66:1689-1697|
|Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351|
|Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346|
|Benson, Constance A; Andersen, Janet W; Macatangay, Bernard J C et al. (2018) Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis 67:1712-1719|
|MacBrayne, Christine E; Marks, Kristen M; Fierer, Daniel S et al. (2018) Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother 73:2112-2119|
|Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459|
|Figueroa, Dominique B; Madeen, Erin P; Tillotson, Joseph et al. (2018) Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses 34:421-429|
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
Showing the most recent 10 out of 130 publications